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Özet
Amaç: Bu çalışmada Tavşanlı Devlet Hastanesi Mikrobiyoloji Laboratuvarı’na 
gönderilen çeşitli klinik örneklerden izole edilen Escherichia coli suşlarının an-
tibiyotik duyarlılıkları retrospektif olarak incelenmiş, bu mikroorganizmala-
rın genişlemiş spektrumlu beta laktamaz (GSBL) üretimlerinin belirlenmesi 
amaçlanmıştır. Gereç ve Yöntem: Kültürlerin tümü etken ve antibiyotik duyar-
lılıkları açısından irdelenmiştir. Bakterilerin tanımlanmasında çeşitli biyokim-
yasal testler ve BBL Crystal E/NF (Beckton Dickinson, ABD) sistemi kullanıl-
mıştır.Antibiyotik duyarlılığı Müller-Hinton Agarda disk diffüzyon yöntemi ile 
CLSI kriterleri doğrultusunda değerlendirilmiştir. GSBL üretiminin araştırıl-
ması için çift disk sinerji  yöntemi kullanılmıştır. Bulgular: Klinik örneklerden 
izole edilen 456 E. coli suşu çalışmaya dahil edilmiştir.  E. coli  suşları gönde-
rildiği örnek türüne göre değerlendirildiğinde en fazla idrar örneğinden izo-
le edildiği görülmektedir. E. coli suşlarının en fazla duyarlı oldukları antibiyo-
tiklerin imipenem, amikasin ve sulbaktam/sefoperazon oldukları belirlenmiş-
tir. Duyarlılığın en düşük olduğu antibiyotik ise ampisilindir. GSBL üretim ora-
nı E. coli’de %15 olarak tespit edilmiştir. Sonuç: Tedavisi pahalı ve güç enfek-
siyonlara neden olan, GSBL üreten  E. coli ve diğer Gram negatif enterik bak-
terilerin GSBL üretim oranları, her merkez tarafından izlenmeli, tedavide ter-
cih edilen geniş spektrumlu beta laktam antibiyotikler dikkatlice kullanılma-
lı, yatan hastalar izole edilmeli, risk altındaki bölümlerinde sürveyans çalış-
ması yapılmalıdır.
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Abstract
Aim: In this study it was aimed to investigate the antibiotic susceptibilities 
and  extended  spectrum  beta  lactamase  production  of  Escherichia  coli 
strains isolated from various clinical samples sent to Tavsanli State Hospital 
Microbiology  Laboratory  retrospectively.  Material  and  Method:  All  of  the 
cultures  were  examined  for  the  agent  and  antibiotic  susceptibilities.  For 
the identification of bacteria, various chemical tests and BBL Crystal E/
NF  (Beckton  Dickinson,  ABD)  system  was  used.  Antibiotic  susceptibilities 
were  investigated  according  to  CLSI  criteria  on  Mueller  Hinton  agar  by 
disc diffusion method. Double disc synergy method was used to investigate 
extended spectrum beta lactamase (ESBL) production. Results: 456 E. coli 
strains  isolated  from  clinical  samples  were  included  in  the  study.  E.  coli 
strains were mostly isolated from urine according to clinical samples. The 
most effective antibiotics against E. coli strains were imipenem, amikacine 
and sulbactam/cefoperazone. The least susceptibility was against ampicillin. 
ESBL  production  rate  was  found  to  be  %15  in  E.  coli.  Discussion:  ESBL 
producing E. coli which are the reason of expensive therapy and difficulties 
in treatment of infections should be monitored for ESBL production ratios 
by all of the centers,  extended spectrum beta lactam antibiotics should bu 
used  carefully  in  treatment,  hospitalized  patients  should  be  isolated  and 
surveillance should be done in the units under risk.
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Introduction
Resistant bacteria are the reason of many hospital and com-
munity acquired infections which lead to morbidity and mortal-
ity. Resistance against beta-lactam antibiotics are increasing 
all over the world including our country [1-3]. Bacteria gain the 
resistance by producing beta-lactamases against this group of 
antibiotics. Beta-lactamase enzyme leads to resistance against 
penicillines,  1st  generation  cephalosporines.  These  enzymes 
may be chromosomal or plasmid mediated [4,5].Extended spec-
trum  beta  lactamases  (ESBL)  hydrolyses  extended  spectrum 
cephalosporins. They arise by mutations in genes for common 
plasmid mediated beta lactamases that alter the configuration 
of the enzyme near its active site to increase the affinity and 
hydrolytic ability of beta lactamases for oxyimino compounds 
while simultaneously weakining the overall enzyme efficiency 
(6)  Hospitals are the most suitable places for these resistance 
genes tobe selected and spread [7]. Hospital infection epide-
mies are seen because of the strains producing extended spec-
trum beta-lactamases which lead to problems in antibiotherapy 
[8]. Double disc synergy is a simple and low cost method to 
determine the presence of extended spectrum beta-lactamase 
[9]. In this study it was aimed to investigate the antibiotic sus-
ceptibilities and extended spectrum beta lactamase production 
of Escherichia coli strains isolated from miscellaneous clinical 
samples sent to Tavsanli State Hospital Microbiology Labora-
tory retrospectively.
Material and Method
In this study microbiogical samples sent to Tavsanli State Hos-
pital Microbiology Laboratory between November 2009 and De-
cember 2011 were evaluated.All of the cultures were examined 
for the agent and antibiotic susceptibilities. For the identifica-
tion of bacteria, various chemical tests and BBL Crystal E/NF 
(Beckton Dickinson, ABD) system was used. Antibiotic suscep-
tibilities were investigated according to CLSI criteria on Muel-
ler Hinton agar by disc diffusion method. Double disc synergy 
method was used to investigate extended spectrum beta lac-
tamase (ESBL) production [9].
Results
Of the 3651 samples sent to laboratory, 877 culture positive 
samples were evaluated. 456 of culture positive samples were 
identified as E. coli. 456 E. coli strains were included in the study 
(Table 1). E. coli was the most common (%52) isolated bacte-
ria. E. coli strains were mostly isolated from urine according to 
clinical samples. Antibiotic susceptibilites of E. coli strains are 
shown in Table 2. The most effective antibiotics against E. coli 
strains  were  imipenem(%99),  sulbactam/cefoperazone(%99)
and amikacine (%96). The least susceptibility was against ampi-
cillin(%28). ESBL production rate was found to be %15 in E. coli.
Discussion
Wide spectrum beta-lactam antibiotics are frequently used be-
cause of their bactericidal effect. But the common usage of this 
group of antibiotics leads to increasing amount of resistant 
strains [3,10]. In this reason, determination of ESBL activity by 
routine simple methods is important for the treatment of these 
infections. ESBL producing strains lead to increase in mortality 
and severe economical deficits [11].
Albayrak et al.[2] showed that the ESBL activity was found to 
be %19 in E. coli strains. Guducuoglu et al. [12] evaluated the 
samples  according  to  the  origin  as  policlinics  or  clinics  and 
showed the ESBL activity as %18 and %47 respectively in E. 
coli strains.  Eryilmaz et al.[13]  showed that the ESBL activity 
in E. coli strains were seen in %18.Mumcuoglu et al. [3]  found 
the ESBL activity in E. coli strains to be %20. Bayramoglu et 
al.[14] found the ESBL activityin %6 of the E.coli strains. Stud-
ies evaluating the ESBL activity in our country show that the 
resistance rates are increasing in time [2,3,12,13].
Halina et al. [15] evaluted 1164 clinical samples in a pediatric 
group of patients. 585 Gram negative rods were isolated and 
229 (%39) of them were found to have ESBL activity by the 
double disc synergy method. ESBL activity was found to be %30 
in E. coli strains. It was thought that the reason for the high 
activity of ESBL resulted from the selected group of patients 
included in the study.
In different studies outside our country, ESBL activity was found 
to be between %5 and 25 by different methods in E. coli strains 
[16-18].
Treatment of resistant strains with new generation antibiotics 
can increase the cost of the drug up to ten folds or more (19).
The cost of extra hospitalization resulting from infections with 
resistant organisms costs about 1,2 billion U.S. dollars in U.S.A. 
(20).
ESBL activity rates in E. coli strains (%15) in our hospital are 
similar to those obtained from national and international stud-
ies. This study also reveals that the most effective antibiotics 
against E. coli are imipenem, amikacine and sulbactam/cefo-
perazone. These antibiotics should not be used routinely, should 
be reserved for multi-drug resistant bacteria [21].
Table 1. Distrubiton of E. colistrains isolated from various clinical samples 
(TAS: Tracheal aspirate)
E.coli (n=456) ESBL + E.coli (n=68)
Urine 291 46
TAS/Sputum 65 10
Wound 51 7
Others 49 6
Total 456 68
Table 2. Antibiotic susceptibilities of E. coli strains (AMC: Amoxicillin/clavulonat, 
CES:  Sulbactam/cefoperazone,  SXT:  Trimethoprim/sulfamethoxazole,  ESBL: 
Extended spectrum beta lactamase)
Antibiotic E.coli(n=456) % ESBL + E.coli(n=68) %
Ampicillin 28 0
AMC 67 0
SXT 59 0
Cefazolin 62 0
Cefuroxime 67 0
Ceftriaxone 70 0
Ceftazidime 70 0
CES 99 94
Gentamicin 77 50
Amikacin 96 82
Ciprofloxacin 68 46
Imipenem 99 94
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ESBL producing E. coli which are the reason of expensive ther-
apy and difficulties in treatment of infections should be moni-
tored for ESBL production ratios by all of the centers,  extended 
spectrum beta lactam antibiotics should bu used carefully in 
treatment, hospitalized patients should be isolated and surveil-
lance should be done in the units under risk.
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